JP2008514224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514224A5 JP2008514224A5 JP2007534175A JP2007534175A JP2008514224A5 JP 2008514224 A5 JP2008514224 A5 JP 2008514224A5 JP 2007534175 A JP2007534175 A JP 2007534175A JP 2007534175 A JP2007534175 A JP 2007534175A JP 2008514224 A5 JP2008514224 A5 JP 2008514224A5
- Authority
- JP
- Japan
- Prior art keywords
- family
- ribonuclease
- ribonuclease protein
- protein
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000006382 Ribonucleases Human genes 0.000 claims 43
- 108010083644 Ribonucleases Proteins 0.000 claims 43
- 102000040430 polynucleotide Human genes 0.000 claims 17
- 108091033319 polynucleotide Proteins 0.000 claims 17
- 239000002157 polynucleotide Substances 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102000002151 Microfilament Proteins Human genes 0.000 claims 7
- 108010040897 Microfilament Proteins Proteins 0.000 claims 7
- 230000027455 binding Effects 0.000 claims 7
- 238000001727 in vivo Methods 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000033115 angiogenesis Effects 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 230000018109 developmental process Effects 0.000 claims 4
- 230000004069 differentiation Effects 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 239000005022 packaging material Substances 0.000 claims 4
- 230000008569 process Effects 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 230000035755 proliferation Effects 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 230000009466 transformation Effects 0.000 claims 4
- 230000005740 tumor formation Effects 0.000 claims 4
- 230000004614 tumor growth Effects 0.000 claims 4
- 230000001093 anti-cancer Effects 0.000 claims 3
- 238000011394 anticancer treatment Methods 0.000 claims 3
- 230000009087 cell motility Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000006228 supernatant Substances 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000000047 product Substances 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000010317 ablation therapy Methods 0.000 claims 1
- 238000002725 brachytherapy Methods 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 238000001126 phototherapy Methods 0.000 claims 1
- 238000002673 radiosurgery Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61370204P | 2004-09-29 | 2004-09-29 | |
| US60/613,702 | 2004-09-29 | ||
| PCT/IL2005/001041 WO2006035439A2 (en) | 2004-09-29 | 2005-09-28 | Recombinant human t2 rnase and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008514224A JP2008514224A (ja) | 2008-05-08 |
| JP2008514224A5 true JP2008514224A5 (https=) | 2008-11-06 |
| JP5069562B2 JP5069562B2 (ja) | 2012-11-07 |
Family
ID=36119279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007534175A Expired - Fee Related JP5069562B2 (ja) | 2004-09-29 | 2005-09-28 | 組換えヒトＴ２ＲＮａｓｅおよびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8039240B2 (https=) |
| EP (1) | EP1805319B1 (https=) |
| JP (1) | JP5069562B2 (https=) |
| AU (1) | AU2005288527B9 (https=) |
| BR (1) | BRPI0516302A (https=) |
| CA (1) | CA2582041C (https=) |
| ES (1) | ES2524601T3 (https=) |
| WO (1) | WO2006035439A2 (https=) |
| ZA (1) | ZA200703313B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE421856T1 (de) * | 1999-08-30 | 2009-02-15 | Yissum Res Dev Co | Gebrauch einer ribonuclease der t2-familie mit actin-bindender aktivität zur hemmung und/oder der umkehrung von proliferation |
| US7811981B2 (en) | 1999-08-30 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
| ATE548621T1 (de) * | 2006-08-01 | 2012-03-15 | Jscd Holding L P | Verbessertes trocknungssystem |
| JP2012507278A (ja) * | 2008-10-30 | 2012-03-29 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | 短縮型ヒトｒｎａｓｅｔ２の大腸菌における効率的発現 |
| US9592539B2 (en) * | 2010-01-05 | 2017-03-14 | Stratasys, Inc. | Support cleaning system |
| EP3049151B1 (en) | 2013-09-27 | 2019-12-25 | Mevion Medical Systems, Inc. | Particle beam scanning |
| US10675487B2 (en) | 2013-12-20 | 2020-06-09 | Mevion Medical Systems, Inc. | Energy degrader enabling high-speed energy switching |
| US9962560B2 (en) | 2013-12-20 | 2018-05-08 | Mevion Medical Systems, Inc. | Collimator and energy degrader |
| US20160340659A1 (en) | 2014-01-30 | 2016-11-24 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. | Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same |
| US9661736B2 (en) | 2014-02-20 | 2017-05-23 | Mevion Medical Systems, Inc. | Scanning system for a particle therapy system |
| US10786689B2 (en) | 2015-11-10 | 2020-09-29 | Mevion Medical Systems, Inc. | Adaptive aperture |
| KR20240095481A (ko) | 2016-03-17 | 2024-06-25 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
| US10925147B2 (en) | 2016-07-08 | 2021-02-16 | Mevion Medical Systems, Inc. | Treatment planning |
| US11103730B2 (en) | 2017-02-23 | 2021-08-31 | Mevion Medical Systems, Inc. | Automated treatment in particle therapy |
| JP6940676B2 (ja) | 2017-06-30 | 2021-09-29 | メビオン・メディカル・システムズ・インコーポレーテッド | リニアモーターを使用して制御される構成可能コリメータ |
| WO2020112890A1 (en) | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Rnaset2 compositions and methods of treatment therewith |
| EP3934751B1 (en) | 2019-03-08 | 2024-07-17 | Mevion Medical Systems, Inc. | Collimator and energy degrader for a particle therapy system |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) * | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) * | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) * | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) * | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) * | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) * | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) * | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) * | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) * | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) * | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) * | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) * | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) * | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) * | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) * | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US5786457A (en) * | 1989-02-23 | 1998-07-28 | Colorado State University Research Foundation | Hormone-nuclease compounds and method for regulating hormone related diseases |
| US5281521A (en) * | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| WO1998039446A2 (en) * | 1997-03-07 | 1998-09-11 | Human Genome Sciences, Inc. | 70 human secreted proteins |
| EP1044266A2 (en) | 1997-12-31 | 2000-10-18 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
| US7101839B1 (en) * | 1999-08-30 | 2006-09-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
| ATE421856T1 (de) | 1999-08-30 | 2009-02-15 | Yissum Res Dev Co | Gebrauch einer ribonuclease der t2-familie mit actin-bindender aktivität zur hemmung und/oder der umkehrung von proliferation |
| US7811981B2 (en) * | 1999-08-30 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
| KR100677108B1 (ko) | 2003-06-12 | 2007-02-01 | 삼성전자주식회사 | 정보 저장매체 |
-
2005
- 2005-09-28 ES ES05789520.3T patent/ES2524601T3/es not_active Expired - Lifetime
- 2005-09-28 WO PCT/IL2005/001041 patent/WO2006035439A2/en not_active Ceased
- 2005-09-28 JP JP2007534175A patent/JP5069562B2/ja not_active Expired - Fee Related
- 2005-09-28 CA CA2582041A patent/CA2582041C/en not_active Expired - Fee Related
- 2005-09-28 US US11/664,132 patent/US8039240B2/en not_active Expired - Fee Related
- 2005-09-28 BR BRPI0516302-1A patent/BRPI0516302A/pt not_active Application Discontinuation
- 2005-09-28 EP EP05789520.3A patent/EP1805319B1/en not_active Expired - Lifetime
- 2005-09-28 AU AU2005288527A patent/AU2005288527B9/en not_active Ceased
-
2007
- 2007-04-23 ZA ZA200703313A patent/ZA200703313B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008514224A5 (https=) | ||
| Mishra et al. | Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis | |
| US12485174B2 (en) | HDAC6-activated macrophages, compositions, and uses thereof | |
| JP5650639B2 (ja) | 腫瘍疾患の治療 | |
| CN112724259B (zh) | 人血清白蛋白与白介素2的融合蛋白及其用途 | |
| CN104109193B (zh) | 一种抗癌活性肽变体及其应用 | |
| US20100178273A1 (en) | Methods and compositions for treating mucositis | |
| WO2009065292A1 (en) | Fusion protein comprising tumor necrosis factor related apoptosis inducing ligand and integrin ligand and use thereof | |
| Xiu et al. | Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma | |
| Oliveira et al. | Exosomes as new therapeutic vectors for pancreatic cancer treatment | |
| Stokłosa et al. | Prospects for p53-based cancer therapy. | |
| US11419894B2 (en) | Modified natural killer cells for the treatment of cancer | |
| CN107206053A (zh) | 用于治疗血细胞减少症或减少血细胞减少症的持续时间的佛波醇酯组合物和方法 | |
| US20230405118A1 (en) | Stat-activated macrophages, compositions, and uses thereof | |
| CN115804853A (zh) | 包含rna分子的组合物及其在制备瘤内注射剂中的用途 | |
| KR20070086663A (ko) | 암 백신 보조제로서 알파 티모신 펩티드류 | |
| Yang et al. | Unravelling the role of ubiquitin-specific proteases in breast carcinoma: insights into tumour progression and immune microenvironment modulation | |
| KR20230157313A (ko) | 인터페론-기반 암 치료 방법 및 약제학적 조합 | |
| JP7412576B2 (ja) | 腎がんの相乗的治療におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の適用 | |
| EP2870135A1 (en) | Pharmaceutical composition comprising amino-phenyl- acetic acid octadec-(z)-9-enyl ester and use thereof for treating tumors | |
| EP3354268B1 (en) | 8-oxo-dgtp for tumor prevention and treatment and applications thereof | |
| KR20230157947A (ko) | 암 재발 방지를 위한 방법 및 약제학적 조합 | |
| CN115803045A (zh) | 用于增强放射治疗的包括含有il-2蛋白和cd80蛋白的融合蛋白的药物组合物 | |
| CN1537012A (zh) | 长五亚基环ptx3在治疗fgf-8介导的肿瘤疾病中的应用 | |
| WO2019200586A1 (en) | Modified nk cells and uses thereof |